Immunomedics 8-K 2010
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of
Date of Report (Date of earliest event reported) January 19, 2010
Registrant's telephone number, including area code: (973) 605-8200
Item 8.01. Other Events.
On January 19, 2010, Immunomedics, Inc., a Delaware corporation (the "Company"), issued a press release announcing the receipt of $5 million from Nycomed, GmbH, for reaching the first clinical milestone event under the license and collaboration agreement, entered into on July 11, 2008, for the worldwide rights to develop, manufacture and commercialize veltuzumab for the treatment of all non-cancer indications. The full text of the press release is attached to this current report on Form 8-K as Exhibit 99.1 hereto and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.